EUROFINS
Comprehensive Bioanalytical Services for Faster Drug Development

In the past couple of years, the global healthcare industry has witnessed a dramatic increase in the number of new compounds that moved from discovery stages into product development. A critical facilitator for this process is Bioanalytics, where scientists use verified methods to identify analytes and metabolites within biological matrices quantitatively. This procedure demonstrates the accuracy, selectivity, stability, and precision of the analysed samples. The aim of bioanalytics is to eliminate poor candidates while moving forward with high-quality components to develop a drug that exhibits a higher rate of success. A global leader in bioanalytics and life science is Eurofins (EPA: ERF)—a biopharmaceutical outsourcing services partner and Contract Research Organisation (CRO) that works with pharmaceutical, chemical, biotechnology, medical device and cosmetic companies.

The group covers the entire drug development chain, owing to its international network of laboratories, testing units, uniform QA systems, and high-quality services. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostics. With over 55,000 staff in more than 50 countries, the group offers a portfolio of 200,000 analytical methods to evaluate the safety, composition, authenticity, and purity of biological substances. The wide range of high-quality services is in coherence with Eurofins’ vision to provide its customers with innovative services that help them grow and enhance their drug development processes. Through R&D and acquisitions, the group integrates the latest developments in biotechnology and analytical chemistry and offers its clients unique analytical solutions that guarantee highly reliable output.

Eurofins was founded in 1987 and has been one of the fastest-growing companies in Europe since then, with an average annual growth rate of more than 29%. Among the plethora of comprehensive services that Eurofins offers, its bioanalytical services are top-rated among life science and pharmaceutical companies across the globe.

Eurofins Pharma Bioanalytical Services, a division of Eurofins, is dedicated to bioanalytical services and solutions. It specialises in PK/TK, ADA, NAb, Biomarker assays and sample analysis and serves the world’s largest pharmaceutical and biopharmaceutical brands. Eurofins is on a mission to enhance its client’s abilities to improve the global health system by combining scientific knowledge and regulatory expertise. The group has greatly demonstrated its commitment to its mission during the covid-19 pandemic. Eurofins Central Laboratory’s clinical testing sites and Kit Packaging and Distribution sites have been providing the global capability to deliver crucial PPE kits and clinical trials to mitigate the spread of the virus. With our 25 years of experience, the laboratory deployed lead, globally standardised processes that enabled GMP and FDA compliant specimen and transportation of these kits worldwide. Eurofins integrated its global clinical testing networks and global testing portfolio with its Vaccine Center of Excellence division and offered molecular infectious disease testing, vaccine safety and efficacy assessment, and biomarker analysis. Furthermore, the group also supported visits with direct-to-subject investigational product distributions and direct-to-subject study-specific specimen collections in coordination with the Home Visit Nursing service. Eurofins is also constantly evaluating the coronavirus to detect emerging variants. The group recently achieved accreditation in The Microfibre Consortium (TMC) testing processes. Eurofins also recently acquired Bioskin GmbH, a specialist in trials for drugs, medical devices, food supplements, and cosmetics. The group will now offer a wide range of complementary and extended services to support its client’s growth and strengthen their operational efficiencies. With such innovative bioanalytical services, it is evident that Eurofins will change the landscape of the global healthcare ecosystems in the post-pandemic era.